MTOR and synovial sarcoma: Since AKT activation is a possible mechanism of resistance to mTOR inhibitors, adding vorinostat (or another HDACi) was proposed as a route to circumvent AKT-mediated resistance to mTOR inhibitors in experimental studies performed on synovial sarcoma cells [208].